MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure

On December 20, 2017, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release that reported the Company had completedenrollment and initial patient dosing in an expanded cohort of the Phase 1 clinical trial evaluating MVT-5873 in combination with first-line chemotherapy for the treatment of pancreatic cancer and other CA 19-9 positive malignancies. The press release is attached hereto as Exhibit 99.1.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

(d)Exhibits.

The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.

MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint   Exhibit 99.1 MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy   – Company plans to announce interim safety and RECIST data Q1 2018 –   SAN DIEGO,…To view the full exhibit click here